Back to top

vaccines: Archive

Sundeep Ganoria

ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential?

IBRX and MRNA hinge on single-drug success, but pipeline depth, growth plans and risks set them apart in the race for biotech upside.

MRKPositive Net Change MRNANegative Net Change IBRXNo Net Change

Zacks Equity Research

VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study

Valneva plunges 37% as Lyme vaccine study shows 70%+ efficacy but misses key statistical target, raising concerns despite plans for regulatory filings.

PFENegative Net Change CPRXNegative Net Change ANIPNegative Net Change VALNNegative Net Change